Back to top

oncology-screening: Archive

Zacks Equity Research

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.

AZNPositive Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change

Zacks Equity Research

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.

LGNDPositive Net Change ANIPPositive Net Change BGNENegative Net Change ANVSPositive Net Change

Zacks Equity Research

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

AZNPositive Net Change BMYPositive Net Change MRKPositive Net Change LGNDPositive Net Change

Zacks Equity Research

Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect

Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.

ANIPPositive Net Change ANABPositive Net Change ARGXPositive Net Change GHNegative Net Change